FDA (Rockville, MD) announced in today\'s Federal Register the release of its final draft of \"Guidance for Industry: Questions and Answers Regarding Adverse Event Reporting and Recordkeeping for Dietary Supplements as Required by the Dietary Supplement and Nonprescription Drug Consumer Protection Act,\" according to the American Herbal Products Association (AHPA; Silver Spring, MD).
FDA (Rockville, MD) announced in today's Federal Register the release of its final draft of "Guidance for Industry: Questions and Answers Regarding Adverse Event Reporting and Recordkeeping for Dietary Supplements as Required by the Dietary Supplement and Nonprescription Drug Consumer Protection Act," according to the American Herbal Products Association (AHPA; Silver Spring, MD).
FDA's final guidance concerns the required submission of written reports to FDA within 15 days by any "responsible person," typically a product marketer, whose product has received report of a serious adverse event. These regulations took full effect in December 2007.
An earlier draft of the guidance was issued in October 2007, and AHPA submitted comments in response to it. The final guidance shows evidence that several of AHPA's comments, including concern with interpretation of official language, were considered and even incorporated into the language of the documents.
FDA's final guidance can be read here: www.fda.gov/Food/GuidanceComplianceRegulatoryInformation/GuidanceDocuments/DietarySupplements/ucm171383.htm
AHPA's 2007 comments can be read here: www.ahpa.org/Portals/0/pdfs/07_1214_AHPAcomments_DS-SAER.pdf
-Robby Gardner
Senate Committee has released the text of 2024 Farm Bill, with changes to hemp regulations
November 19th 2024The U.S. Senate Committee on Agriculture, Nutrition, & Forestry has introduced the Rural Prosperity and Food Security Act, which will serve as the Senate’s draft for the 2024 Farm Bill.
NPA’s lawsuit against FDA on NMN stayed pending agency’s decision on citizen petition
November 6th 2024The court has granted a joint motion for stay filed by NPA and FDA, pending the agency's decision on the citizen petition asking FDA to reverse its stance on NMN's status as a dietary ingredient.